Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 12/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485169 | 0.92 | CXCR2 (0.52) | CXCR2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL484817 | 0.91 | CXCR2 (0.56) | CXCR2MAPK1 | |
| SCHEMBL5179601 | 0.88 | CXCR2 (0.54) | CXCR2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL485107 | 0.87 | CXCR2 (0.53) | CXCR2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL485184 | 0.87 | CXCR2 (0.57) | CXCR2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL485248 | 0.86 | CXCR2 (0.62) | CXCR2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL485481 | 0.86 | CXCR2 (0.58) | CXCR2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL485119 | 0.86 | CXCR2 (0.61) | CXCR2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL485325 | 0.85 | CXCR2 (0.51) | CXCR2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL485103 | 0.85 | CXCR2 (0.48) | CXCR2LMNAKDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184177-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885LMNA 4616/4885KDM4E 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.